Serina Therapeutics
SER
30 hedge funds and large institutions have $3.29M invested in Serina Therapeutics in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
0.01% more ownership
Funds ownership: 0.36% → 0.36% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 32 → 30 (-2)
22% less capital invested
Capital invested by funds: $4.24M → $3.29M (-$950K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.5K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$31.3K |
| 3 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$9.02K |
| 4 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
+$7.91K |
| 5 |
SIS
Strategic Investment Solutions
Orland Park,
Illinois
|
+$7.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.56K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.07K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$344 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$89 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| $160 | -$4.07K | -154 | -96% |
|
|
LC
27
Lindbrook Capital
Calabasas,
California
| $117 | – | – | – |
|
28
BNP Paribas Financial Markets
Paris,
France
| $50 | – | – | – |
|
|
AWM
29
Avior Wealth Management
Omaha,
Nebraska
| $20 | – | – | – |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$9.56K | -304 | Closed |
|
|
31
Bank of America
Charlotte,
North Carolina
| – | -$89 | -3 | Closed |
|
SER Hedge Fund Activity: Q3 2023 in Review
30 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q3 2023, worth a combined $3.29M — down 22% from $4.24M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SER and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 9 added.
The largest buyer was Geode Capital Management, adding an estimated $32.5K. The largest seller was Susquehanna International Group, cutting an estimated $14.6K.
- 30 institutional investors held Serina Therapeutics (SER) as of Q3 2023, down from 32 in Q2 2023.
- Funds reported $3.29M of Serina Therapeutics stock for Q3 2023, down 22% quarter-over-quarter.
- 0 funds opened new Serina Therapeutics positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest Serina Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $32.5K added.
- The largest Serina Therapeutics seller in Q3 2023 was Susquehanna International Group, an estimated $14.6K sold.
Based on aggregated 13F filings for Q3 2023.